Chinese stocks are blowing up, and the buying isn’t slowing. Both foreign funds and local investors are throwing cash into the market. The Shanghai Composite just hit its highest point in ten years, and the Hang Seng Index in Hong Kong has already climbed 30% in 2025. That makes it the best run since 2017. […]Chinese stocks are blowing up, and the buying isn’t slowing. Both foreign funds and local investors are throwing cash into the market. The Shanghai Composite just hit its highest point in ten years, and the Hang Seng Index in Hong Kong has already climbed 30% in 2025. That makes it the best run since 2017. […]

China’s stock market is surging as both local and foreign investors jump in

2025/09/27 02:50
3 min read

Chinese stocks are blowing up, and the buying isn’t slowing. Both foreign funds and local investors are throwing cash into the market.

The Shanghai Composite just hit its highest point in ten years, and the Hang Seng Index in Hong Kong has already climbed 30% in 2025. That makes it the best run since 2017.

And it’s not just coming from funds, it’s coming from everyday people who’ve had enough of low bank returns and a dead property market. The whole thing is turning fast.

According to CNN, the buying frenzy took off on September 24, 2024, the date now known in China’s financial scene as the “9.24 performance.” That’s when Pan Gongsheng, the central bank governor, and other senior finance officials held a rare joint press briefing. They made it clear they were stepping in.

Beijing drives rally with new policy and media play

A few days ago, another media briefing was held by top financial officials. They said China’s capital markets were gaining new friends globally, pointing to rising foreign interest.

Cathie Wood’s Ark Investment Management confirmed it reopened a position in Alibaba, the first time in four years. It was listed in their daily trading report.

The government also isn’t just watching from the sidelines. They’re pushing big institutions to get involved. Chinese regulators have told insurers and state-backed mutual funds to start buying more stocks. These are institutions that normally sit things out. Not this time.

The aim is to turn China’s stock market into something closer to what the U.S. has, a place where people grow their wealth, not just take chances.

Still, retail buyers are doing most of the work. And they’re doing it fast. Hou Yujie, who runs a hanfu rental business near the Forbidden City, is one of them. She recently moved 10% of her money into stocks and made a full month’s salary in a matter of days. “Interest rates for bank deposits are so low I don’t even want to bother,” she said. “Stocks are a hot topic right now.”

Investors pile in as other options dry up

There aren’t many other options. Real estate in China is still struggling. Investment outside the country is locked up with tight restrictions. That leaves stocks. And people are noticing the country’s progress in things like AI and drones.

Hou said, “AI and drones have been developing fast in China. I hear there is great potential for those stocks.” Policy experts see real intent from the top. Hao Hong, chief investment officer at Lotus Asset Management, said:

But even with the buying spree, old scars haven’t healed. Many remember the crash ten years ago that wiped out fortunes. That memory still haunts retail traders. And it’s a big reason why some still treat the market like a gamble.

Hao said, “Many of the retail investors still believe that it’s a gamble. It’s a casino. No one believes that it’s a long-term investment. It’s very different from the U.S.”

HSBC says retail buyers make up 90% of China’s daily trading volume. In the United States, it’s just 20%. That means the swings in China are bigger, louder, and way more emotional. That also means the rally is fragile. If enough people get spooked, everything could reverse.

KEY Difference Wire helps crypto brands break through and dominate headlines fast

Market Opportunity
Threshold Logo
Threshold Price(T)
$0.00679
$0.00679$0.00679
-1.16%
USD
Threshold (T) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26